WASHINGTON (CN) - Pfizer will sell off rights to four drugs to clear its $16 billion acquisition of Hospira of antitrust concerns, the FTC said in a settled complaint.
Pfizer will divest itself of assets and rights to its generic acetylcysteine inhalation solution, and to three injectable Hospira drugs: clindamycin phosphate, an antibiotic; voriconazole, an anti-fungal drug; and melphalan hydrochloride, a chemotherapy drug. All four come in branded and generic versions.
Alvogen, a U.S.-based generic drugmaker, is expected to buy rights to all the drugs.
The companies will have three years to complete the divestitures.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.